Abstract
A 26-year-old, healthy, female nurse on no regular medication, developed a mildly pruritic, erythematous, annular patch with faint, central clearing on her left shoulder (Figure 1a). The patient had received the first dose of the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine in the same arm 15 days prior to the development of the lesion. The injection site was 7cm distal to the evolving patch. Over the span of 2 days, the patch developed a shallow, central erosion surrounded by a halo of erythema (Figure 1b) and subsequently started to resolve spontaneously. The patient had also experienced facial flushing 15 minutes after the vaccine was administered.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
